Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $58.76 Average Target Price from Analysts

Key Points

• Kymera Therapeutics has received a consensus recommendation of "Buy" from 19 analysts, with an average 1-year price target of $58.76.
• Insider activity showed significant investments, with Director Bros. Advisors Lp Baker purchasing 655,500 shares at $44 each, increasing ownership by 12%.
• Despite a 2.5% decline in stock price recently, Kymera reported disappointing earnings with a loss of ($0.95) per share, falling short of estimates.

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus rating of "Buy" by the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $58.7647.

A number of equities analysts have issued reports on the company. BTIG Research reiterated a "buy" rating and set a $59.00 target price on shares of Kymera Therapeutics in a report on Thursday, June 26th. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and set a $60.00 price objective (up from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Wells Fargo & Company dropped their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday, June 26th. Finally, Guggenheim reiterated a "buy" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il acquired 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the purchase, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. This trade represents a 12.78% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker acquired 655,500 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the purchase, the director owned 6,117,295 shares of the company's stock, valued at $269,160,980. The trade was a 12.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 16.01% of the company's stock.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its position in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after acquiring an additional 770 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after acquiring an additional 1,083 shares during the last quarter. State of Wyoming acquired a new stake in shares of Kymera Therapeutics in the 4th quarter worth about $45,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Kymera Therapeutics in the 4th quarter worth about $55,000.

Kymera Therapeutics Stock Down 0.8%

NASDAQ:KYMR traded down $0.35 during trading hours on Friday, hitting $43.14. 35,457 shares of the stock were exchanged, compared to its average volume of 733,575. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $53.27. The company has a market capitalization of $3.08 billion, a P/E ratio of -12.44 and a beta of 2.17. The company's 50 day moving average is $43.35 and its two-hundred day moving average is $37.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business's quarterly revenue was down 55.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.58) EPS. On average, equities research analysts expect that Kymera Therapeutics will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.